Solid Tumor
Conditions
Keywords
Solid tumor, Immune Checkpoint Inhibitor, immune-related Adverse Event
Brief summary
This trial is a multicentric, prospective cohort study of 150 patients aiming to model evolution of toxicity over time in patients with solid tumor and starting first cycle of Immune Checkpoint Inhibitor (ICI) treatment. The study will be conducted on a population of patients treated with ICI in the context of routine care. The follow-up during the treatment period and the clinical, biological and radiological assessments will be performed according to the standard of each centre. The study data (immune-related adverse events) will be collected during each administration of the treatment. A questionnaire will be completed by the patient before the treatment administrations. Patients will be followed until disease progression or up to 12 months of treatment.
Interventions
OTHERPatients starting a treatment by ICI
Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30) before treatment administration and during the 12 months of treatment period, at the following time points: * every 6 weeks for treatment regimen administered every 2 or 3 weeks * at Weeks 6, 12, 20, 24 for treatment regimen administered every 4 weeks
Sponsors
Institut Claudius Regaud
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age \> or = 18 years old 2. Patient with a solid tumor whatever the organ 3. Patient receiving an Immune Checkpoint Inhibitor treatment 4. Patient starting first cycle of Immune Checkpoint Inhibitor treatment whatever the treatment line 5. Patient affiliated to the french social security system 6. Patient must provide written informed consent prior to inclusion in the study and any study-specific procedure
Exclusion criteria
1. Patient who must receive a treatment other than Immune Checkpoint Inhibitor 2. Patient with contraindication to the use of a checkpoint inhibitor (e.g., auto immune disorders requiring an immunosuppressive therapy) 3. Pregnant or breastfeeding women 4. Any psychological, familial, geographical or sociological condition potentially preventing the medical follow-up and/or study procedures 5. Patient protected by law
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of toxicities evaluated according to the classification of the Common for Toxicity Criteria for Adverse Events (CTCAE) V4.03 | 12 months by patient |
Secondary
| Measure | Time frame |
|---|---|
| Time to appearance of toxicity | 12 months by patient |
| Rate of patients for which treatment was restarted among those who had stopped treatment for the management of an immune-related Adverse Event (irAE) | 12 months by patient |
| Quality of life using the QLQ-C30 questionnaire | 12 months by patient |
Countries
France
Outcome results
None listed